search
Back to results

Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

Primary Purpose

Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer

Status
Completed
Phase
Phase 1
Locations
Brazil
Study Type
Interventional
Intervention
BZ371A
Sponsored by
Biozeus Biopharmaceutical S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Erectile Dysfunction Following Radical Prostatectomy focused on measuring Erectile Dysfunction, Radical Prostatectomy, Prostate Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • Men or women
  • Body mass index > 19 and < 28.5 Kg/m2
  • Is able to understand the Informed Consent Form (ICF)

Exclusion Criteria:

  • Women in their menstrual period;
  • Diseases that interfere with the absorption, distribution and excretion of drugs, such as history or presence of hepatic or renal diseases;
  • Presence of active genital lesions or sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, Human Papillomavirus, and others) that impair analysis of local adverse effects on the genitalia;
  • History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patients with heart disease (including a history of angina and/or heart failure) and nephropathies;
  • Findings on ECG and/or laboratory tests that, in the investigator's judgment, are considered the research volunteer's participation or may interfere with the analysis of the study of the study;
  • Blood pressure (BP) outside the limits considered safe: systolic BP (SBP) 90 - 140 mmHg and diastolic BP diastolic BP (DBP) 60 - 90 mmHg, except for situations such as "white coat syndrome";
  • Any disease or condition or physical finding that the investigator considers significant and that increases the risk
  • Any disease or condition or physical finding that the investigator considers significant and that increases the risk of participation of the research volunteer or may interfere with the results.

Sites / Locations

  • Azidus Brasil Pesquisa Científica e Desenvolvimento

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Healthy Patients

Arm Description

Healthy patients receiving topical application of BZ371A

Outcomes

Primary Outcome Measures

Cmax
Peak Plasma Concentration
T1/2
Terminal half-life of BZ371A
AUC
Area under the curve (AUC) of plasma/serum/blood drug concentration-time curve
Clearance (CL)
Clearance of BZ371A
Vd
Distribution Volume of BZ371A
Adverse Effects Evaluation
Adverse effect evaluation of compound use and application
Physical Exam
Number of participants with abnormal physical exam findings
Change in SBP
Change in Systolic Blood Pressure
Change in DBP
Change in Diastolic Blood Pressure
Change in Heart Rate (HR)
Change in Heart Rate
Change in Respiratory Rate (RR)
Respiratory Rate
Change in Temperature
Temperature measurements
Basal chest electrocardiogram (ECG)
Number of participants with abnormal ECG readings
Blood Evaluation
Number of participants with abnormal laboratory test results
Urine Evaluation
Number of participants with abnormal urinalysis

Secondary Outcome Measures

Full Information

First Posted
February 22, 2022
Last Updated
January 24, 2023
Sponsor
Biozeus Biopharmaceutical S.A.
Collaborators
Azidus Brasil Scientific Research and Development Ltda
search

1. Study Identification

Unique Protocol Identification Number
NCT05332340
Brief Title
Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered
Official Title
Phase 1 Clinical Trial Study to Evaluate Pharmacokinetics and Safety Profile of BZ371A in a Gel Formulation, Applied on Healthy Men and Women Genitals
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Completed
Study Start Date
November 16, 2022 (Actual)
Primary Completion Date
November 30, 2022 (Actual)
Study Completion Date
November 30, 2022 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Biozeus Biopharmaceutical S.A.
Collaborators
Azidus Brasil Scientific Research and Development Ltda

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to evaluate pharmacokinetics, safety and tolerability profile of BZ371A topically administered in healthy patients.
Detailed Description
Prostate cancer remains one of the most prevalent cancer in men. For its treatment, recent technological advances demonstrate that the most effective treatment is the Radical Prostatectomy (RP) procedure. However, although curative for Prostate Cancer, can result in damage to the cavernosal nerves. The cavernosal autonomic nerves travel posterolaterally to the prostate to enter the penis and regulate blood flow and hence erection. Thus, damage caused by RP will affect NO tissue release and blood flow regulation, causing erectile dysfunction. BZ371A has the ability to restore local blood flow regulation by a new and innovative mechanism of action and, therefore, has potential to be a supportive therapy for RP patients (restoring the erectile function). Thus, this study has the purpose to evaluate safety, tolerability and pharmacokinetics of a BZ371A single dose, topically administrated at the genital area.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction, Prostate Cancer, Radical Prostatectomy
Keywords
Erectile Dysfunction, Radical Prostatectomy, Prostate Cancer

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
12 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Healthy Patients
Arm Type
Experimental
Arm Description
Healthy patients receiving topical application of BZ371A
Intervention Type
Drug
Intervention Name(s)
BZ371A
Intervention Description
Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
Primary Outcome Measure Information:
Title
Cmax
Description
Peak Plasma Concentration
Time Frame
0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
Title
T1/2
Description
Terminal half-life of BZ371A
Time Frame
0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
Title
AUC
Description
Area under the curve (AUC) of plasma/serum/blood drug concentration-time curve
Time Frame
0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
Title
Clearance (CL)
Description
Clearance of BZ371A
Time Frame
0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
Title
Vd
Description
Distribution Volume of BZ371A
Time Frame
0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose
Title
Adverse Effects Evaluation
Description
Adverse effect evaluation of compound use and application
Time Frame
All adverse effect will be collected from the beginning of the study up to one week after drug administration
Title
Physical Exam
Description
Number of participants with abnormal physical exam findings
Time Frame
Baseline and 1 week
Title
Change in SBP
Description
Change in Systolic Blood Pressure
Time Frame
Baseline and 1 week
Title
Change in DBP
Description
Change in Diastolic Blood Pressure
Time Frame
Baseline and 1 week
Title
Change in Heart Rate (HR)
Description
Change in Heart Rate
Time Frame
Baseline and 1 week
Title
Change in Respiratory Rate (RR)
Description
Respiratory Rate
Time Frame
Baseline and 1 week
Title
Change in Temperature
Description
Temperature measurements
Time Frame
Baseline and 1 week
Title
Basal chest electrocardiogram (ECG)
Description
Number of participants with abnormal ECG readings
Time Frame
Baseline and 1 week
Title
Blood Evaluation
Description
Number of participants with abnormal laboratory test results
Time Frame
Baseline and 1 day
Title
Urine Evaluation
Description
Number of participants with abnormal urinalysis
Time Frame
Baseline and 1 week

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Men or women Body mass index > 19 and < 28.5 Kg/m2 Is able to understand the Informed Consent Form (ICF) Exclusion Criteria: Women in their menstrual period; Diseases that interfere with the absorption, distribution and excretion of drugs, such as history or presence of hepatic or renal diseases; Presence of active genital lesions or sexually transmitted disease (STD) (such as herpes, gonorrhea, candidiasis, Human Papillomavirus, and others) that impair analysis of local adverse effects on the genitalia; History of symptomatic hypotension, or diseases that increase the risk of symptomatic hypotension, such as patients with heart disease (including a history of angina and/or heart failure) and nephropathies; Findings on ECG and/or laboratory tests that, in the investigator's judgment, are considered the research volunteer's participation or may interfere with the analysis of the study of the study; Blood pressure (BP) outside the limits considered safe: systolic BP (SBP) 90 - 140 mmHg and diastolic BP diastolic BP (DBP) 60 - 90 mmHg, except for situations such as "white coat syndrome"; Any disease or condition or physical finding that the investigator considers significant and that increases the risk Any disease or condition or physical finding that the investigator considers significant and that increases the risk of participation of the research volunteer or may interfere with the results.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Regina M Doi
Organizational Affiliation
Azidus Brasil Pesquisa Científica e LTDA
Official's Role
Principal Investigator
Facility Information:
Facility Name
Azidus Brasil Pesquisa Científica e Desenvolvimento
City
Valinhos
State/Province
São Paulo
Country
Brazil

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered

We'll reach out to this number within 24 hrs